Have you heard the one about the guy who founded a biotech startup in the middle of Manhattan? Around a repurposed, hydrolysable, insoluble small molecule? To treat massive strokes, traumatic brain injury, and other neuro indications? Using a highly translatable rodent model? During the financial crisis? Unpartnered? And who spent $1M per year to generate randomized, placebo-controlled, double-blind PhII results that show a 50% reduction in mortality from strokes that were too big for other trials and too late for other treatments?
For a long time, Remedy was one guy and one drug. But that drug, Cirara™, combats swelling in the central nervous system – a root cause of morbidity and mortality in multiple diseases. Today Cirara™ is still investigational, but in line to be the first therapeutic advance in the stroke field in over 20 years. And an in-progress Ph II trial in TBI has it poised to tackle football as well.
Sven doesn’t have a swelled head – and he doesn’t want anyone else to have one either.